The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Research output: Contribution to journalArticle


WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of


Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Publication statusPublished - 28 Sep 2011

Sustainable Development Goals